Stay updated on Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial page.

Latest updates to the Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial page
- Check2 days agoChange DetectedThe page’s revision/version indicator was updated from v3.5.2 to v3.5.3, reflecting a change in the site release rather than study details.SummaryDifference0.1%

- Check9 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check38 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check45 days agoChange DetectedUpdated the page revision from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check74 days agoChange DetectedThe page now shows revision v3.4.2, replacing the previous v3.4.1. This is a minor metadata update that does not affect content, functionality, or user interactions.SummaryDifference0.1%

- Check81 days agoChange DetectedA minor revision label was updated from v3.4.0 to v3.4.1; no substantive study details or content were altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial page.